Onconetix, Inc.
ONCO
Rank in Stocks
#32702
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed... Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Share Price
$3.58
Last synced: 2026-11-09
Market Cap
$1.28M
Change (1 day)
-48.49%
Change (1 year)
-97.38%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Onconetix, Inc. (ONCO)
Category
Healthcare
Operating Margin for Onconetix, Inc. (ONCO)
Operating Margin as of November 2026 TTM: -1,265.55%
According to Onconetix, Inc.'s latest financial reports, its current operating margin (TTM) is -1,265.55%. At the end of 2025 the company had an operating margin of -778.16%.
Operating Margin history for Onconetix, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,265.55% | 62.63% |
| 2025 | -778.16% | -65.23% |
| 2024 | -2,237.96% | -96.37% |
| 2023 | -61,634.47% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.03% |
US
|
|
| -149.01% | -99.88% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Onconetix, Inc.'s operating margin
What is Onconetix, Inc.'s operating margin?
Onconetix, Inc.'s operating margin is -1,265.55%, as of Nov 2026.
What was Onconetix, Inc.'s operating margin in 2025?
In 2025, Onconetix, Inc.'s operating margin was -778.16%, compared with -2,237.96% in 2024.
How has Onconetix, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Onconetix, Inc.'s operating margin was highest in 2022 (0.00%) and lowest in 2023 (-61,634.47%).
How does Onconetix, Inc.'s operating margin compare with similar companies?
Onconetix, Inc.'s operating margin (-1,265.55%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.